• Vaccine Name: Bovine herpesvirus 1 GPI protein vaccine
• Target Pathogen: Bovine herpesvirus 1
• Target Disease: Infectious bovine rhinotracheitis
• Vaccine Ontology ID: VO_0011383
• Type: Subunit vaccine
• Status: Research
• Antigen: Bovine herpesvirus 1 envelope glycoprotein I
• US7 gene engineering:
  • Type: Recombinant protein preparation
  • Description: A truncated BHV-1 envelope gpI protein was secreted into the culture supernatant of D17 cells transfected with the gpI gene lacking the coding sequence for the transmembrane region (TMR). The transmembrane domain is essential for gpI stability in the envelope, virus infectivity and, most probably, natural killer cell recognition (Gao et al., 1994).
  • Detailed Gene Information: Click Here.

Cattle Response

• Vaccination Protocol: The 20 calves were divided into two groups (ten animals in each group) and immunized as follows:group 1 was primed intramusculary (i.m.) with concentrated gpI (17 ug/animal) emulsified in complete Freund's adjuvant, and boosted by intranasal (i.n.) aerosolization (Laboratory spray unit, Gelman Sciences Inc., Ann Arbor, MI) with 100yg gpI plus 20 ug cholera toxin subunit B (CTB) per animal at the 3rd and 9th weeks. Then, 30 yg of gpI emulsified in incomplete Freund's adjuvant was administered subcutaneously at the base of the ear at the 15th week. Alternatively, group 2 was treated as above with the same amount of non-transfected D17 cell culture supernatant concentrated from a volume equal to that of the gpI supernatant. The antibody levels in sera and nasal secretions were tested at 2-week intervals after each vaccination to assess the gpI immune response (Gao et al., 1994).
• Challenge Protocol: All animals were challenged with 5 x 10^5 p.f.u, of virulent Cooper strain BHV-1 (ATCC VR864) by intranasal aerosolization. Nasal swabs were collected daily for 12 days and viral replication and shedding were detected by titration on MDBK cells. The animals were monitored for signs of disease (fever, nasal mucosal lesions, nasal discharge, conjunctivitis and depression) (Gao et al., 1994).
• Efficacy: mmunization of calves with this truncated gpI protein induced gpI-specific nasal IgA, IgG1, serum neutralizing antibodies and gpI-specific peripheral lymphocyte proliferation. All immunized calves were protected from clinical disease after BHV-1 challenge. Further, nine of ten immunized calves had no intranasal viral shedding. One animal shed a minimal amount of virus following challenge, but produced no antibodies to other viral proteins as evidenced by immunoprecipitation of 35S-labelled viral proteins by sera from virus-challenged animals (Gao et al., 1994).